Range of qualified patients: CDEC discussed the uncertainty in the quantity of sufferers with reasonably serious to severe hemophilia B in Canada qualified for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some individuals who're categorized as owning mild or average disease can have a critical bleeding phenotype, https://hemgenix71582.articlesblogger.com/58419630/examine-this-report-on-hemgenix